Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 3409 - 3416 of 12093 results

Deal with Me: Transaction Insurance Leaders Chat with Matt and Dan
February 23, 2021| News

Companies Beef Up Risk Disclosures As Biden Era Begins
February 22, 2021| News

European Commission Publishes Draft Adequacy Decision for Transfers of Personal Data from the EU to the UK
February 19, 2021| Blog| Viewpoint

Navigating Voluntary COVID-19 Vaccination Programs & Incentives
February 19, 2021| Blog| Viewpoint

TCPA Regulatory Update — Compliance Dates Established for Reassigned Numbers Database Reporting Requirements
February 18, 2021| Article| Viewpoint

TCPA Regulatory Update — Industry Shows Support for FCC Hospital Robocall Blocking Recommendations
February 18, 2021| Article| Viewpoint

Health Care Enforcement Year in Review & 2021 Outlook
February 18, 2021| News

Webinar Recording: FDA in 2021: A Look Ahead
February 18, 2021| Webinar| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
